Connection

William Hrushesky to Animals

This is a "connection" page, showing publications William Hrushesky has written about Animals.
Connection Strength

0.783
  1. Cancer as a changed tissue's way of life (when to treat, when to watch and when to think). Future Oncol. 2016 Mar; 12(5):647-57.
    View in: PubMed
    Score: 0.038
  2. Measuring stem cell circadian rhythm. Methods Mol Biol. 2015; 1235:81-95.
    View in: PubMed
    Score: 0.036
  3. Circadian transcription profile of mouse breast cancer under light-dark and dark-dark conditions. Cancer Genomics Proteomics. 2010 Nov-Dec; 7(6):311-22.
    View in: PubMed
    Score: 0.027
  4. Clock genes and cancer. Integr Cancer Ther. 2009 Dec; 8(4):303-8.
    View in: PubMed
    Score: 0.025
  5. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther. 2009 Dec; 8(4):387-97.
    View in: PubMed
    Score: 0.025
  6. Circadian time-dependent tumor suppressor function of period genes. Integr Cancer Ther. 2009 Dec; 8(4):309-16.
    View in: PubMed
    Score: 0.025
  7. Discovery of candidate genes and pathways that may help explain fertility cycle stage dependent post-resection breast cancer outcome. Breast Cancer Res Treat. 2009 Nov; 118(2):345-59.
    View in: PubMed
    Score: 0.025
  8. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009 Oct; 26(7):1323-39.
    View in: PubMed
    Score: 0.025
  9. Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem. 2009 Mar; 145(3):289-97.
    View in: PubMed
    Score: 0.023
  10. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res. 2008 Nov; 6(11):1786-93.
    View in: PubMed
    Score: 0.023
  11. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat. 2009 Sep; 117(2):423-31.
    View in: PubMed
    Score: 0.023
  12. Seasonal modulation of post-resection breast cancer metastasis. Breast Cancer Res Treat. 2008 Sep; 111(2):219-28.
    View in: PubMed
    Score: 0.022
  13. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 2006 Aug; 5(8):2023-33.
    View in: PubMed
    Score: 0.020
  14. Developmental abnormalities in multiple proliferative tissues of Apc(Min/+) mice. Int J Exp Pathol. 2006 Jun; 87(3):227-36.
    View in: PubMed
    Score: 0.020
  15. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther. 2005 Jul; 4(7):1065-75.
    View in: PubMed
    Score: 0.018
  16. Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat. 2005 May; 91(1):47-60.
    View in: PubMed
    Score: 0.018
  17. Sex cycle modulates cancer growth. Breast Cancer Res Treat. 2005 May; 91(1):95-102.
    View in: PubMed
    Score: 0.018
  18. Re: Melatonin and breast cancer: a prospective study. J Natl Cancer Inst. 2004 Jun 02; 96(11):888-9.
    View in: PubMed
    Score: 0.017
  19. Fertility cycle influence on surgical breast cancer cure. Breast Cancer Res Treat. 2002 Sep; 75(1):65-72.
    View in: PubMed
    Score: 0.015
  20. Circadian coordination of cancer growth and metastatic spread. Int J Cancer. 1999 Oct 29; 83(3):365-73.
    View in: PubMed
    Score: 0.012
  21. Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle. Reprod Toxicol. 1999 Sep-Oct; 13(5):413-20.
    View in: PubMed
    Score: 0.012
  22. Menstrual timing of breast cancer surgery. Am J Surg. 1998 Mar; 175(3):245-61.
    View in: PubMed
    Score: 0.011
  23. Menstrual cycle timing of breast cancer resection. Recent Results Cancer Res. 1996; 140:27-40.
    View in: PubMed
    Score: 0.010
  24. Circadian rhythms and cancer chemotherapy. Crit Rev Eukaryot Gene Expr. 1996; 6(4):299-343.
    View in: PubMed
    Score: 0.010
  25. Square pegs in round holes. Int J Cancer. 1995 Sep 04; 62(5):651-2.
    View in: PubMed
    Score: 0.009
  26. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr; 95(4):1650-9.
    View in: PubMed
    Score: 0.009
  27. Cancer chronotherapy: is there a right time in the day to treat? J Infus Chemother. 1995; 5(1):38-43.
    View in: PubMed
    Score: 0.009
  28. Circadian dynamics of tumor necrosis factor alpha (cachectin) lethality. J Exp Med. 1994 Sep 01; 180(3):1059-65.
    View in: PubMed
    Score: 0.009
  29. Circadian pharmacodynamics of anticancer therapies. Clin Chem. 1993 Nov; 39(11 Pt 2):2413-8.
    View in: PubMed
    Score: 0.008
  30. Circadian cancer therapy. J Clin Oncol. 1993 Jul; 11(7):1403-17.
    View in: PubMed
    Score: 0.008
  31. Circadian cancer pharmacodynamics. Ann Ist Super Sanita. 1993; 29(4):705-10.
    View in: PubMed
    Score: 0.008
  32. The multifrequency (circadian, fertility cycle, and season) balance between host and cancer. Ann N Y Acad Sci. 1991; 618:228-56.
    View in: PubMed
    Score: 0.007
  33. Temporally optimizable delivery systems--sine qua non for molecular medicine. Preface. Ann N Y Acad Sci. 1991; 618:xi-xvii.
    View in: PubMed
    Score: 0.007
  34. Prohibitin as an oxidative stress biomarker in the eye. Int J Biol Macromol. 2010 Dec 01; 47(5):685-90.
    View in: PubMed
    Score: 0.007
  35. Cleavage of the retinal pigment epithelium-specific protein RPE65 under oxidative stress. Int J Biol Macromol. 2010 Aug 01; 47(2):104-8.
    View in: PubMed
    Score: 0.006
  36. Melatonin reprogrammes proteomic profile in light-exposed retina in vivo. Int J Biol Macromol. 2010 Aug 01; 47(2):255-60.
    View in: PubMed
    Score: 0.006
  37. Menstrual influence on surgical cure of breast cancer. Lancet. 1990 Apr 21; 335(8695):984.
    View in: PubMed
    Score: 0.006
  38. Determination of the therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst. 1990 Mar 07; 82(5):386-93.
    View in: PubMed
    Score: 0.006
  39. Local immunosuppression of the vascularized graft. Surgery. 1990 Feb; 107(2):209-14.
    View in: PubMed
    Score: 0.006
  40. Pharmacodynamics of local heparin infusion in a canine renal allograft model. J Pharmacol Exp Ther. 1990 Feb; 252(2):733-8.
    View in: PubMed
    Score: 0.006
  41. Cancer chronotherapy: a drug delivery challenge. Prog Clin Biol Res. 1990; 341A:1-10.
    View in: PubMed
    Score: 0.006
  42. In this issue: circadian disruption and cancer. Integr Cancer Ther. 2009 Dec; 8(4):295-7.
    View in: PubMed
    Score: 0.006
  43. Neuroprotective role of erythropoietin by antiapoptosis in the retina. J Neurosci Res. 2009 Aug 01; 87(10):2365-74.
    View in: PubMed
    Score: 0.006
  44. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18; 81(2):135-45.
    View in: PubMed
    Score: 0.006
  45. Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin. Invest New Drugs. 1988 Dec; 6(4):273-83.
    View in: PubMed
    Score: 0.006
  46. Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst. 1988 Oct 05; 80(15):1232-7.
    View in: PubMed
    Score: 0.006
  47. Splenocyte natural killer cell activity and metastatic potential are inversely dependent on estrous stage. Surgery. 1988 Aug; 104(2):398-403.
    View in: PubMed
    Score: 0.006
  48. Estrous influence on surgical cure of a mouse breast cancer. J Exp Med. 1988 Jul 01; 168(1):73-83.
    View in: PubMed
    Score: 0.006
  49. The effects of surgery on tumor growth: a century of investigations. Ann Oncol. 2008 Nov; 19(11):1821-8.
    View in: PubMed
    Score: 0.006
  50. Methylene blue protects intestinal mucosa from free radical-mediated sublethal radiation damage. Free Radic Biol Med. 1988; 5(4):207-13.
    View in: PubMed
    Score: 0.005
  51. Circadian susceptibility-resistance cycles to radiation and their manipulability by methylene blue. Pharmacol Ther. 1988; 39(1-3):397-402.
    View in: PubMed
    Score: 0.005
  52. Timing may be a critical factor in drug therapy. Cancer Treat Rep. 1987 Dec; 71(12):1321.
    View in: PubMed
    Score: 0.005
  53. Racial disparities in breast cancer outcome: insights into host-tumor interactions. Cancer. 2007 Nov 01; 110(9):1880-8.
    View in: PubMed
    Score: 0.005
  54. Circadian pattern of continuous FUDR infusion reduces toxicities. Prog Clin Biol Res. 1987; 227B:357-73.
    View in: PubMed
    Score: 0.005
  55. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 1986; 3(1):55-64.
    View in: PubMed
    Score: 0.005
  56. Cancer chronomics III. Chronomics for cancer, aging, melatonin and experimental therapeutics researchers. J Exp Ther Oncol. 2006; 6(1):73-84.
    View in: PubMed
    Score: 0.005
  57. Cyclosporine timing and kidney damage. N Engl J Med. 1985 Jul 18; 313(3):184.
    View in: PubMed
    Score: 0.005
  58. Circadian timing of cancer chemotherapy. Science. 1985 Apr 05; 228(4695):73-5.
    View in: PubMed
    Score: 0.005
  59. Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet. 1985 Mar 09; 1(8428):565-7.
    View in: PubMed
    Score: 0.005
  60. Circadian toxicology of cyclosporin. Toxicol Appl Pharmacol. 1985 Jan; 77(1):181-5.
    View in: PubMed
    Score: 0.004
  61. 24-hour mean pulse. Simple predictor of doxorubicin-induced cardiac damage. Am J Med. 1984 Sep; 77(3):399-406.
    View in: PubMed
    Score: 0.004
  62. Creation of a stable mammary tumor cell line that maintains fertility-cycle tumor biology of the parent tumor. In Vitro Cell Dev Biol Anim. 2004 Jul-Aug; 40(7):187-95.
    View in: PubMed
    Score: 0.004
  63. Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure. Chronobiol Int. 1984; 1(1):59-66.
    View in: PubMed
    Score: 0.004
  64. The clinical application of chronobiology to oncology. Am J Anat. 1983 Dec; 168(4):519-42.
    View in: PubMed
    Score: 0.004
  65. Circadian time dependence of cisplatin urinary kinetics. Clin Pharmacol Ther. 1982 Sep; 32(3):330-9.
    View in: PubMed
    Score: 0.004
  66. Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res. 1982 Mar; 42(3):945-9.
    View in: PubMed
    Score: 0.004
  67. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 2001 Mar; 92(3):328-36.
    View in: PubMed
    Score: 0.003
  68. Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer. 2000 Nov 01; 88(3):479-85.
    View in: PubMed
    Score: 0.003
  69. Distinct circadian time structures characterize myeloid and erythroid progenitor and multipotential cell clonogenicity as well as marrow precursor proliferation dynamics. Exp Hematol. 1998 Jun; 26(6):523-33.
    View in: PubMed
    Score: 0.003
  70. Current status of the therapy of advanced renal carcinoma. J Surg Oncol. 1977; 9(3):277-88.
    View in: PubMed
    Score: 0.003
  71. Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc Natl Acad Sci U S A. 1996 May 28; 93(11):5460-5.
    View in: PubMed
    Score: 0.002
  72. Evaluation of chemotherapeutic agents in a new murine renal carcinoma model. J Natl Cancer Inst. 1974 Apr; 52(4):1117-22.
    View in: PubMed
    Score: 0.002
  73. Investigation of a new renal tumor model. J Surg Res. 1973 Nov; 15(5):327-36.
    View in: PubMed
    Score: 0.002
  74. A murine renal cell carcinoma. J Natl Cancer Inst. 1973 Apr; 50(4):1013-25.
    View in: PubMed
    Score: 0.002
  75. Carcinogenicity of ethylmethanesulfonate. J Natl Cancer Inst. 1972 Oct; 49(4):1077-83.
    View in: PubMed
    Score: 0.002
  76. Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. Transplantation. 1992 Jan; 53(1):12-9.
    View in: PubMed
    Score: 0.002
  77. Local prednisolone infusion of canine renal allografts. Transplantation. 1989 Dec; 48(6):1072-5.
    View in: PubMed
    Score: 0.002
  78. Local immunosuppression with reduced systemic toxicity in a canine renal allograft model. Transplantation. 1989 Dec; 48(6):936-43.
    View in: PubMed
    Score: 0.002
  79. Feasibility of vascular catheter placement for intrarenal infusion in a canine autotransplant model. Transplant Proc. 1989 Feb; 21(1 Pt 1):1125-6.
    View in: PubMed
    Score: 0.001
  80. Hormonal and chemotherapeutic treatment of prostatic carcinoma; Dunning adenocarcinoma of the prostate in Copenhagen-Fischer rats. Oncology. 1985; 42(1):48-54.
    View in: PubMed
    Score: 0.001
  81. Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism. Cancer Treat Rep. 1982 Nov; 66(11):1933-8.
    View in: PubMed
    Score: 0.001
  82. Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol. 1982 May; 18(5):471-7.
    View in: PubMed
    Score: 0.001
  83. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982 Mar; 42(3):950-5.
    View in: PubMed
    Score: 0.001
  84. Time-varying effects in mice and rats of several synthetic ACTH preparations. Chronobiologia. 1980 Apr-Jun; 7(2):211-26.
    View in: PubMed
    Score: 0.001
  85. Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin. Chronobiologia. 1980 Apr-Jun; 7(2):227-44.
    View in: PubMed
    Score: 0.001
  86. Influence of hormone therapy on rats treated with the carcinogen ethylmethanesulphonate. Res Commun Chem Pathol Pharmacol. 1974 Jan; 7(1):25-30.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.